Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)
Wolfe Research initiated coverage of Tyra Biosciences (NASDAQ:TYRA) with a Peer Perform rating and no price target on May 19, saying dabogratinib could meet the CR bar for LR IR NMIBC but remains dependent on safety de-risking. Tyra’s May 13 Q1 update reported a $39.3M net loss, $383.5M cash, and funding into 2H 2028.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the initiation framing: Peer Perform with no price target and explicit emphasis on remaining “on the fence” pending safety de-risking.
Market read
Overall, the article is more about positioning and risk framing than a new fundamental datapoint; near-term trading is likely to track safety-related catalysts and ongoing Phase 2 readouts.
What to watch
The article highlights cash funding into 2H 2028, so dilution risk may be lower than peers—potentially supporting downside resilience despite the cautious rating.
Background
The piece combines an analyst initiation (Wolfe Research) with a recap of TYRA’s Q1 dabogratinib program progress (including SURF303 dosing and 2027 initial results timing).
Ticker impact
Wolfe Research initiated Tyra Biosciences with a Peer Perform rating, while the article also reiterates TYRA’s Q1 dabogratinib progress and funding runway.
Limited immediate catalyst; expect sentiment to hinge on upcoming 2026 safety de-risking and Phase 2 readouts rather than the initiation note alone.
The note is a rating initiation without a target, and the article’s other specifics (cash runway, dosing milestones) largely restate previously reported Q1 results; the only forward-looking emphasis is safety de-risking and 2026 readouts.
Market effects
Reinforces the precision oncology/bio-pharma narrative that valuation depends on safety de-risking alongside efficacy endpoints.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Minimal; drug-development milestones are company-specific.
Counterpoint
Peer Perform could be viewed as underestimating upside if dabogratinib’s safety profile improves faster than expected and efficacy clears key response thresholds.
Key entities
- companyTyra Biosciences, Inc.
Precision oncology developer of dabogratinib; reported Q1 progress and has cash funding into 2H 2028.
- analyst_firmWolfe Research
Initiated coverage on TYRA with a Peer Perform rating and no price target.
- drug_candidatedabogratinib
TYRA’s precision oncology asset; discussed as potentially achieving CR bar for LR IR NMIBC while safety remains the gating factor.
